Maximilien Baron1, Benoit Peyronnet2, Annabelle Aublé1, Juliette Hascoet2, Evelyne Castel-Lacanal3, Gabriel Miget4, Sabine Le Doze5, Thomas Prudhomme6, Andrea Manunta2, Jean-Nicolas Cornu1, Xavier Gamé6. 1. Department of Urology, University of Rouen , Rouen , France. 2. Department of Urology, University of Rennes , Rennes , France. 3. Department of Physical Medicine and Rehabilitation, University of Toulouse , Toulouse , France. 4. Department of Physical Medicine and Rehabilitation, University of Rouen , Rouen , France. 5. Department of Physical Medicine and Rehabilitation, Functional Re-Education and Rehabilitation Center Le Normandy , Granville , France. 6. Department of Urology, University of Toulouse , Toulouse , France.
Abstract
PURPOSE: Data are lacking on long-term outcomes of intradetrusor injections of botulinum toxin A for neurogenic detrusor overactivity. The aim of this study was to assess the outcomes of intradetrusor injections of botulinum toxin A for neurogenic detrusor overactivity after more than 10 years of followup. MATERIALS AND METHODS: We retrospectively reviewed the charts of all consecutive neurological patients who had received onabotulinumtoxin A or abobotulinumtoxin A intradetrusor injections for neurogenic detrusor overactivity between January 2002 and November 2007 at a total of 3 academic centers. The primary outcome measure was the 10-year discontinuation rate. Other outcomes of interest were failure, reasons for discontinuation and subsequent treatments of neurogenic detrusor overactivity. Discontinuation-free and failure-free survival was estimated by Kaplan-Meier analyses. RESULTS: A total of 140 patients were included in study. The 10-year discontinuation-free and failure-free survival rates were 49.1% and 73%, respectively. The most common reason for discontinuation was failure in 43.7% of cases, which was primary and secondary in 17.2% and 26.5%, respectively. Secondary failure occurred after a median of 8 injections and a median of 80.1 months from the first injection. Other reasons for discontinuation were patient decision in 28.1% of patients, nonbotulinum toxin A related improvement of urinary incontinence in 14.1%, neurological condition progression in 12.5% and an adverse event in 1.6%. Discontinuation-free survival was significantly poorer in patients with spina bifida than in patients with multiple sclerosis or spinal cord injury (p = 0.02). CONCLUSIONS: More than half of the patients with neurogenic detrusor overactivity discontinued intradetrusor botulinum toxin A within the first 10 years after the initial injection. Patients with spina bifida are at high risk for discontinuation.
PURPOSE: Data are lacking on long-term outcomes of intradetrusor injections of botulinum toxin A for neurogenic detrusor overactivity. The aim of this study was to assess the outcomes of intradetrusor injections of botulinum toxin A for neurogenic detrusor overactivity after more than 10 years of followup. MATERIALS AND METHODS: We retrospectively reviewed the charts of all consecutive neurological patients who had received onabotulinumtoxin A or abobotulinumtoxin A intradetrusor injections for neurogenic detrusor overactivity between January 2002 and November 2007 at a total of 3 academic centers. The primary outcome measure was the 10-year discontinuation rate. Other outcomes of interest were failure, reasons for discontinuation and subsequent treatments of neurogenic detrusor overactivity. Discontinuation-free and failure-free survival was estimated by Kaplan-Meier analyses. RESULTS: A total of 140 patients were included in study. The 10-year discontinuation-free and failure-free survival rates were 49.1% and 73%, respectively. The most common reason for discontinuation was failure in 43.7% of cases, which was primary and secondary in 17.2% and 26.5%, respectively. Secondary failure occurred after a median of 8 injections and a median of 80.1 months from the first injection. Other reasons for discontinuation were patient decision in 28.1% of patients, nonbotulinum toxin A related improvement of urinary incontinence in 14.1%, neurological condition progression in 12.5% and an adverse event in 1.6%. Discontinuation-free survival was significantly poorer in patients with spina bifida than in patients with multiple sclerosis or spinal cord injury (p = 0.02). CONCLUSIONS: More than half of the patients with neurogenic detrusor overactivity discontinued intradetrusor botulinum toxin A within the first 10 years after the initial injection. Patients with spina bifida are at high risk for discontinuation.
Authors: O Blé; J Levy; C Lefèvre; M A Perrouin-Verbe; A Even; L Le Normand; E Chartier Kastler; B Perrouin-Verbe; P Denys; C Joussain Journal: World J Urol Date: 2022-06-01 Impact factor: 4.226
Authors: Jacquie Maignel; Vincent Martin; Rana Assaly; Mathieu L Vogt; Kevin Retailleau; Fraser Hornby; Alexandra Laugerotte; Stéphane Lezmi; Pierre Denys; Johannes Krupp; Charles Joussain Journal: Toxins (Basel) Date: 2022-01-21 Impact factor: 4.546
Authors: Charles Joussain; Olivier Le Coz; Andrey Pichugin; Peggy Marconi; Filip Lim; Mariaconcetta Sicurella; Keith Foster; François Giuliano; Alberto L Epstein; Alejandro Aranda Muñoz Journal: Int J Mol Sci Date: 2022-07-30 Impact factor: 6.208